Shares of Nuvalent NUVL have soared nearly 20% in the past week owing to encouraging updates on its two investigational ...

Biotech Nuvalent unveiled updates on two experimental cancer medicines over the weekend. Analysts say each could be the best ...

Nuvalent shows promise with strong clinical data for zidesamtinib and NVL-655 in treating ROS1- and ALK-positive NSCLC. Read ...

Nuvalent achieved positive data from the phase 1/2 ALKOVE-1 study using NVL-655 for the treatment of patients with ALK-mutant ...

Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the closing ...

Nuvalent, Inc. (NUVL), a company focused on cancer treatment, announced on Monday that it has commenced an underwritten public ...

We recently compiled a list of the 10 Largest Biotech Hedge Funds and Their Top Stock Picks. In this article, we are going to ...

Scattered investor qualms about Nuvalent Inc.’s largely upbeat data during the European Society for Medical Oncology (ESMO) ...

Nuvalent shares are trading lower by 6.2% during Tuesday's session. The company priced a $500 million public offering of 5 million shares at $100 each. Nuvalent Inc NUVL shares are trading lower ...

Nuvalent Inc. (NUVL) announced the pricing of an upsized underwritten public offering of 5 million shares of Class A common stock at ...

We recently compiled a list of the 10 Worst Cancer Stocks To Buy Now According to Short Sellers. In this article, we are ...

Shares of Nuvalent NUVL have soared nearly 20% in the past week owing to encouraging updates on its two investigational therapies. Both therapies target previously treated non-small cell lung ...